I agree 109%….It was stated in short message....something I'm ni5 good at lol.
recappjng the points.
they are waiting & expecting FDA type c meeting date/ follow up etc.....very soon.
the first patient to be enrolled in cohurt #5, again this quarter aka , with next 3 weeks.
O.S,. Numbers from bracelet.
Now, it is in black & white , plain English, on the Onc PSF website presentation . The Gobblet trials are continuing alongside Roche.
Whst is equally clear...says TBD. For the MBc phase 3.
again my 100% agreement, they need a business development deal, ASAP.
They did state in the pdf report run rate of cash well into 2025.
great news. I'm not certain on the month of 2025?
in addition to other things they must show evidence if a minium if 12 months of cash flow, to maintain listing.
The recent trading volumes, have not shown indication of ATM funding.
if so, very minimal.
knowing full well, the above catalysts are great for negotiations, the cash position is not.
all time critical.
either a full on licensing deal, parteship or buyout.
alternatively very out of the box thinking.
qualifying, I'm not in favour & doubt would happen.
1. taking Onc private , removing various financial restraints .
2.a significant bought deal.
3. general re- organization. Creating a subsidiary, with Onc as lead owner, yet outdpside $$$ , as the phase 3 financial resort.
respectfully, I doubt any of those options will happen.
what you will not see, is a R/ S on the NAS
recall brad T has been brought back in some capacity.
when president he was 100% against the R/S idea to get Nas listing.
Matt, at 2017/18; or so, seeing at that time oppotunities with MBc, did go that route as we know.
in very quick succession.
they did R/ S , Nas listing, then a major bought deal..followed by massive shorting.
end of 2019, the famous short squeeze spike.
SP was going up at times more than .50 to .80/ day.
enough about history...
Now is what matters.
i see a partership or buyout as a sensible option.
financcially something is needed soon.